Lipocine

Editor's note: This story has been updated with the correct PDUFA date for Lipocine Inc.  After seeing some strength earlier on, biotech stocks came under pressure in the week ended Aug. 21. With the earnings season tapering and not much of noise on the coronavirus front, the sector...

Lipocine Inc (NASDAQ: LPCN) is a nano-cap specialty pharmaceutical company whose lead product candidate is an oral testosterone replacement therapy called LPCN 1021. Shares of Lipocine were trading higher by more than 12 percent ahead of Monday's opening bell after the company announced the...

Shares of Lipocine Inc (NASDAQ: LPCN), a specialty pharmaceutical company that focuses on developing products in the are of men's and women's health, has seen its stock rise nearly 40 percent over the past two weeks. September 26: Positive Top-Line Results The company announced...